

# Ji-Yan Liu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9520102/publications.pdf>

Version: 2024-02-01

81  
papers

1,726  
citations

361413

20  
h-index

315739

38  
g-index

85  
all docs

85  
docs citations

85  
times ranked

2105  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. <i>European Urology Oncology</i> , 2023, 6, 228-232.	5.4	11
2	Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03. <i>Clinical Cancer Research</i> , 2022, 28, 489-497.	7.0	36
3	Neoadjuvant tislelizumab combination chemotherapy for advanced penile cancer: A case report. <i>Asian Journal of Surgery</i> , 2022, , .	0.4	1
4	Clinicopathologic features, treatment, survival, and prognostic factors of combined hepatocellular and cholangiocarcinoma: A nomogram development based on SEER database and validation in multicenter study. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1559-1566.	1.0	8
5	Immune-Related Pneumonitis Was Decreased by Addition of Chemotherapy with PD-1/L1 Inhibitors: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTs). <i>Current Oncology</i> , 2022, 29, 267-282.	2.2	1
6	Recombinant humanized Anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma (POLARIS-03 study): Two-year survival update and biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 508-508.	1.6	0
7	Immunological effect of tyrosine kinase inhibitors on the tumor immune environment in non-â€‘small cell lung cancer (Review). <i>Oncology Letters</i> , 2022, 23, 165.	1.8	8
8	Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study. <i>Immunotherapy</i> , 2022, 14, 309-320.	2.0	0
9	Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management. <i>International Journal of Ophthalmology</i> , 2022, 15, 646-656.	1.1	12
10	Identifying tumor antigens and immuno-â€‘subtyping in colon adenocarcinoma to facilitate the development of <scp>mRNA</scp> vaccine. <i>Cancer Medicine</i> , 2022, , .	2.8	3
11	Efficacy and safety of raltitrexed plus S-1 <i>versus</i> regorafenib in patients with refractory metastatic colorectal cancer: a real-world propensity score matching study. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210982.	3.2	0
12	Epidemiology, Treatment, and Outcome of Pancreatic Squamous Cell Carcinoma and Pancreatic Adenocarcinoma: A Propensity Score-Matching Analysis Based on SEER-Database. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211065.	1.9	0
13	RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4520-4520.	1.6	23
14	Toripalimab (anti-PD-1) monotherapy as a second-line treatment for patients with metastatic urothelial carcinoma (POLARIS-03): Two-year survival update and biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4566-4566.	1.6	0
15	Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. <i>Cancer Science</i> , 2021, 112, 305-313.	3.9	62
16	Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-â€‘Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 43-51.	7.0	125
17	Integrated Molecular Characterization of Fumarate Hydratase-â€‘deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1734-1743.	7.0	54
18	Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer. <i>International Immunopharmacology</i> , 2021, 91, 107296.	3.8	20

#	ARTICLE	IF	CITATIONS
19	Bevacizumab Combined with Sâ€¹ and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study. <i>Oncologist</i> , 2021, 26, e1320-e1326.	3.7	3
20	Epigenetic Quantification of DNA 5â€¹Hydroxymethylcytosine Using DNA Hybridizationâ€¹Based Singleâ€¹Molecule Immunofluorescent Imaging. <i>Small Methods</i> , 2021, 5, e2100061.	8.6	8
21	Expression and prognostic value of epithelialâ€¹toâ€¹mesenchymal transition and cancer stem cell markers in primary lesions and liver metastases of colorectal cancers. <i>Oncology Letters</i> , 2021, 22, 499.	1.8	1
22	Firstâ€¹line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component. <i>Cancer Medicine</i> , 2021, 10, 3388-3402.	2.8	5
23	Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castrationâ€¹resistant prostate cancer patients. <i>Prostate</i> , 2021, 81, 721-727.	2.3	15
24	An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4584-4584.	1.6	16
25	Anterior wall adenocarcinoma of bladder with similar clinicopathological and prognostic characteristics as common bladder carcinomas should not be treated as or classified into urachal adenocarcinomas. <i>Cancer Medicine</i> , 2021, 10, 5415-5428.	2.8	4
26	Phase I clinical trial of <sc>HC</sc>â€¹119: A deuterated form of enzalutamide. <i>International Journal of Cancer</i> , 2021, 149, 1473-1482.	5.1	9
27	Clinical features, treatment, and prognosis of different histological types of primary small bowel adenocarcinoma: A propensity score matching analysis based on the SEER database. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2108-2118.	1.0	9
28	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 317.	17.1	68
29	The Role of Neoantigens in Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 682325.	2.8	14
30	Inflammationâ€¹nutritional markers of peripheral blood could predict survival in advanced nonâ€¹smallâ€¹cell lung cancer patients treated with <sc>PD</sc>â€¹1 inhibitors. <i>Thoracic Cancer</i> , 2021, 12, 2914-2923.	1.9	13
31	Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 5262.	12.8	40
32	Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110562.	1.3	5
33	Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management. <i>Frontiers in Immunology</i> , 2021, 12, 800879.	4.8	54
34	Predictive Risk Factors and Online Nomograms for Synchronous Colon Cancer With Liver Metastasis. <i>Frontiers in Oncology</i> , 2020, 10, 1681.	2.8	10
35	<p>Prognostic Values of Radiosensitivity Genes and CD19 Status in Gastric Cancer: A Retrospective Study Using TCGA Database</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 365-373.	0.7	6
36	Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 548867.	2.8	2

#	ARTICLE	IF	CITATIONS
37	iRGD decorated liposomes: A novel actively penetrating topical ocular drug delivery strategy. <i>Nano Research</i> , 2020, 13, 3105-3109.	10.4	22
38	A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype. <i>Oncogene</i> , 2020, 39, 6871-6878.	5.9	2
39	Increased proportion of the squamous cell carcinoma component is associated with worse survival in resected gastric adenosquamous carcinoma. <i>Medicine (United States)</i> , 2020, 99, e21980.	1.0	2
40	Chemoradiotherapy Is Inferior to Chemotherapy Alone in Adjuvant Setting for Signet Ring Cell Containing Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 570268.	2.8	3
41	Single-molecule quantification of 5-methylcytosine and 5-hydroxymethylcytosine in cancer genome. <i>View</i> , 2020, 1, e9.	5.3	11
42	Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial. <i>Frontiers in Oncology</i> , 2020, 10, 664.	2.8	19
43	Super-resolution observation of lysosomal dynamics with fluorescent gold nanoparticles. <i>Theranostics</i> , 2020, 10, 6072-6081.	10.0	43
44	Bevacizumab plus S-1 and raltitrexed for refractory metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16024-e16024.	1.6	0
45	Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Results of an open-label phase II clinical study Polaris-03.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5040-5040.	1.6	5
46	Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. <i>Molecular Biomedicine</i> , 2020, 1, 16.	4.4	4
47	Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Preliminary results of an open-label phase II clinical study (POLARIS-03).. <i>Journal of Clinical Oncology</i> , 2020, 38, 504-504.	1.6	1
48	Selected proliferation markers correlated with dynamics of growth in colorectal cancer. <i>European Journal of Cancer Prevention</i> , 2019, 28, 181-187.	1.3	1
49	AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy. <i>Prostate</i> , 2019, 79, 1553-1562.	2.3	22
50	Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment. <i>Frontiers in Pharmacology</i> , 2019, 10, 1184.	3.5	50
51	S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial. <i>Oncologist</i> , 2019, 24, 591-e165.	3.7	11
52	Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. <i>Frontiers in Pharmacology</i> , 2019, 10, 1350.	3.5	75
53	Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial. <i>Oncologist</i> , 2019, 24, e702-e708.	3.7	70
54	A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4509-4509.	1.6	32

#	ARTICLE	IF	CITATIONS
55	14-3-3zeta is involved in the anticancer effect of metformin in colorectal carcinoma. <i>Carcinogenesis</i> , 2018, 39, 493-502.	2.8	4
56	Advanced Scrotal Extramammary Paget's Disease Treated With Apatinib: A Case Report. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e339-e342.	1.9	4
57	Expression and epigenetic regulatory mechanism of BNIP3 in clear cell renal cell carcinoma. <i>International Journal of Oncology</i> , 2018, 54, 348-360.	3.3	16
58	Comparative study of (Asp)7-CHOL-modified liposome prepared using pre-insertion and post-insertion methods for bone targeting <i>in vivo</i> . <i>Journal of Drug Targeting</i> , 2017, 25, 149-155.	4.4	6
59	Prospective randomized phase II study of FOLFIRI versus FOLFOX7 in advanced gastric adenocarcinoma: a Chinese Western Cooperative Gastrointestinal Oncology Group Study. <i>Oncotarget</i> , 2017, 8, 97890-97899.	1.8	5
60	Acquired tumor cell resistance to sunitinib by increased invasion and epithelial-mesenchymal transition in LL/2 murine lung cancer. <i>Oncotarget</i> , 2017, 8, 68270-68279.	1.8	4
61	The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy. <i>Oncotarget</i> , 2017, 8, 55374-55383.	1.8	30
62	Recurrent Penile Squamous Cell Carcinoma Successfully Treated With Cetuximab, Chemotherapy, and Radiotherapy. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e135-e137.	1.9	6
63	Higher Expression of Proteins in IGF/IR Axes in Colorectal Cancer is Associated with Type 2 Diabetes Mellitus. <i>Pathology and Oncology Research</i> , 2016, 22, 773-779.	1.9	14
64	Prognostic factors of intraperitoneal chemotherapy for peritoneal carcinomatosis of gastric cancer: A retrospective study from a single center. <i>Oncology Letters</i> , 2016, 11, 3501-3507.	1.8	2
65	Clinical significance of serum CA125 in diffuse malignant mesothelioma. <i>SpringerPlus</i> , 2016, 5, 368.	1.2	7
66	A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection. <i>Gastric Cancer</i> , 2016, 19, 245-254.	5.3	7
67	Gemcitabine and Paclitaxel for Primary Bladder Carcinoma in Renal Transplant Recipients: A Case Report. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e423-e425.	1.9	0
68	The green tea polyphenol EGCG potentiates the antiproliferative activity of sunitinib in human cancer cells. <i>Tumor Biology</i> , 2016, 37, 8555-8566.	1.8	39
69	Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4565-4565.	1.6	6
70	Prospective randomized phase II study of FOLFIRI versus FOLFOX7 in advanced gastric adenocarcinoma: A Chinese Western Cooperative Gastrointestinal Oncology Group study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1-1.	1.6	1
71	The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer. <i>Prostate</i> , 2015, 75, 1247-1254.	2.3	49
72	A phase I study of adjuvant intensity-modulated radiotherapy with concurrent paclitaxel and cisplatin for cervical cancer patients with high risk factors. <i>Medical Oncology</i> , 2015, 32, 247.	2.5	4

#	ARTICLE	IF	CITATIONS
73	Raltitrexed combined with bevacizumab in heavily pretreated metastatic colorectal cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2013, 9, 727.	0.9	1
74	Loss of RASSF1A Expression in Colorectal Cancer and Its Association with K-ras Status. <i>BioMed Research International</i> , 2013, 2013, 1-7.	1.9	16
75	Sorafenib treatment of Asian patients with advanced renal cell carcinoma (RCC) in daily practice: Subset analysis of the large non-interventional PREDICT study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4628-4628.	1.6	2
76	Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1597-1604.	4.2	135
77	Gemcitabine and Cisplatin in Advanced Nasopharyngeal Carcinoma: A Pilot Study. <i>Cancer Investigation</i> , 2005, 23, 123-128.	1.3	17
78	Immunotherapy with Recombinant Xenogeneic Vascular Endothelial Growth Factor as a Vaccine Combined Low-Dose Adriamycin Induces Synergistic Antitumor Efficacy in EL4 Lymphoma Model.. <i>Blood</i> , 2005, 106, 4811-4811.	1.4	0
79	Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. <i>Blood</i> , 2003, 102, 1815-1823.	1.4	107
80	Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. <i>Nature Medicine</i> , 2000, 6, 1160-1166.	30.7	224
81	Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy. <i>Future Oncology</i> , 0, , .	2.4	1